No products in the cart.
Noctura 400 has racked up 2 million hours of patient use and has maintained CE for 10 years
Noctura 400 first received a CE mark under the EU Medical Device Directive in 2014, for the treatmen...
CEO Richard Kirk talks about the development and successes of Noctura 400. With an in depth understanding of the diabetic retinopathy disease pathway and the patients that Noctura 400 has helped treat Richard warmly recounts their journeys, but also reflects on the potential of Noctura 400 not just in the UK, but around the world.
